Residual Risk of Cardiovascular Complications in Case of Adequate Lipid-Lowering Therapy

Аннотация

This article is devoted to the problems of residual risk of cardiovascular complications development for high and very high risk patients under adequate lipid-lowering pharmacotherapy in spite of cholesterol and low-density lipoproteins target level achievement. Along with classic risk factors the special attention is given to lipoprotein (a) [LP(a)] as the most aggressive factor of cardiovascular system atherosclerotic diseases development and their complications. Great importance is attached to lipidopheresis.

Список литературы

1. Obshchaya zabolevaemost' vzroslogo naseleniya Rossii v 2012 godu. Statisticheskiematerialy.Chast' IV. M., 2013.(In Russ.).

2. Castelli WP. Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol1992;2(l–2):23–28.

3. Multiple Risk Factor Intervention Trial Group. The Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA1976;235(8):825–827.

4. Keys A, Menotti A, Aravanis C et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med. 1984;13:141–154.

5.The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice. 2016 Guidelines on Cardiovascular disease prevention in clinical practice. Eur Heart J.

doi:10.1093/eurheartj/ehw106.

6. Cholesterol Treatment Trialists (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet2012;380:581–590.

7. Cholesterol Treatment Trialists (CTT) Collaborators. Fulcher J, O’Connel R., Voysey M. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet2015;385:1397–1405.

8. Ference BA, Majeed F, Penumetcha R et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015 Apr 21;65(15):1552-61.

doi: 10.1016/j.jacc.2015.02.020

9. ZubarevMY, SusekovAV. Reduction program residual (residual) vascular risk: the R3i project (the Residual Risk Reduction Initiative). Part I. risk Factors of residual. Kardiologiia. 2010;50(8):76-83. (In Russ.).

10. Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551—559.

11. Goettsch WG, Yin DD, Alemao E et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Current Medical Research and Opinion,2014;20(7):1025–1033.

12. Riesen WF, Darioli R, Noll G. Lipid-lowering therapy: strategies for improving Compliance. Curr Med Res Opin2004;20(2):165–173.

13. Bauwerns M, Schneider MP, Nanchen D. Adherence to statins: updates and practical proposals. Rev Med Suisse. 2016;12(508):445–448.

14. Stulc T, Ceška R, Gotto A. Jr. Statin Intolerance: the Clinician’s Perspective. Curr Atheroscler Rep2015;17(12):69.

doi: 10.1007/s11883-015-0552-3

15. Stroes ES, Thompson PD, Corsini A et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;(36):1012—1022.

doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18.

16. Banach M, Rizzo M., Toth PP et al. Statin intolerance – an attempt at a unified definition. Position paper from an International. Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.

17. Pedro-Botet J, Schaefer EJ, Bakker Arkema RG. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158:183–193.

18. Sniderman A, Thanassoulis G, Couture P et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology. 2012;6(4):303—309.

19. Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–1066.

20.Awan Z, Seidah NG, MacFadyen JG et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem.2012;58(1):183—9.

doi: 10.1373/clinchem.2011.172932

21. Bauwerns M, Schneider MP, Nanchen D. Adherence to statins: updates and practical proposals. Rev Med Suisse. 2016;12(508):445–448.

22. Albers JJ, Slee A, O'Brien KD. Relatiohship of Apolipoproteins A-l and B, and Lipoprotein (a) to cardio-vascular outcomes: the AIM-HIGH trial. J Am Coll Cardiol. 2013;62 (17):1575—1579.

23. Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551—559.

24. Khera AV, Everett BM, Caulfield MP et al. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635—642.

25. Koschinsky M, Marcovina SM. Lipoprotin(a). In: C. Ballantyne, ed. Clinical lipidology: a companion to Braunwald's heart disease. Philadelphia: Saunders Elsevier,2009:130—143.

26. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. JAmCollCardiol. 2012;60(8):716—721.

27. Diagnostika i korrektsiya narushenii lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Rossiiskie rekomendatsii Komiteta ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. M.: Medicina, 2004. (In Russ.).

28. Murase T, Okubo M, Amemiya-Kudo M. Impact of markedly elevated serum lipoprotein (a) levels on the risk of coronary heart disease. Metabolism. 2007;56(9):1187—1191.

29. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10(2):240—245.

30. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report on the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clinical Chemistry. 2003;49(11):1785—1796.

31. Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisens e inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340—351.

32. Ezhov MV, Safarova MS, Afanasieva OI et al. Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235(2):477—482.

33. Gerasimov AM, Czerkawska OV, Maslennikov MA, Kochetov A. Cellular mechanisms, clinical and morphological risk factors for the development of restenosis. Vestnik Rentgenologii i Radiologii. 2011;(4):58—65. (In Russ.).

34. Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). CircJ.2006;70(2):156—162.

35. Ezhov MV, Safarova MS, Malchin YG et al. The relation of high level of lipoprotein (a) with the patency of the coronary arteries within the first year after percutaneous coronary interventions. Klinitsist. 2011;1:18—24. (In Russ.).

36. Ezhov VM, Safarova MS, Afanasieva 01 et al. Lipoprotein(a) as a predictor of adverse prognosis in long-term periods after coronary bypass surgery. Kardiologiia. 2011;51(1):18—22. (In Russ.).

37. Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004 Dec;256(6):482—90.

doi: 10.1111/j.1365-2796.2004.01405.x

38. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314—345.

39. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J.2013;34(17):1279— 1291.

40. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082—1098.

41. Aronow WS. PCSK9 Inhibitors. Cardiovasc Pharm Open Access.2015;(4):4.

42. Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract.2014;29(1):3—12.

43. Bosch T. Therapeutic apheresis—state of the art in the year 2005. Therapeutic Apheresis and Dialysis.2005;9(6):4590—468.

44. Hovland A, Marcovina S, Hardersen R et al. Three different LDL apheresis columns efficiently and equally reduce lipoprotein (a) concentra-tions in patients with familial hypercholesterolemia and small apolipoprotein (a) particles. J Clin Apher. 2012;46(l):73—76.

45. Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl. 2015;(18):215—225.

46. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis.Atherosclerosis. 2010;208(2):317—321.

47. Borberg H. 26 Years of LDL — Apheresis: a review of experience transfusion and apheresis. Science. 2009;41(1):49—59.

48. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J.2010;31(23):2844—2853.

49.Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229—239.

50. Lopukhin YuM, Archakov Al, Vladimirov YA, Kogan EM. Cholesterinos. Moscow: Medicine, 1983. (In Russ.).

Для цитирования

Simerzin VV, Fatenkov OV, Gagloeva IV, Galkina MA, Panisheva YaAResidual Risk of Cardiovascular Complications in Case of Adequate Lipid-Lowering TherapyScience & Innovations in Medicine. 2018;2(10):1925.

Request

Send an online application form to the publication

Send